Form 4: Gilead CEO O'Day Exercises RSUs, Acquires Shares

Gilead Sciences CEO Daniel O'Day exercised restricted stock units and acquired common stock, with a portion sold to cover tax liabilities.

Summary

• Daniel P. O'Day, Chairman & CEO of Gilead Sciences, Inc., engaged in transactions on September 10, 2025.
• He exercised 10,427 Restricted Stock Units (RSUs), converting them into 10,427 shares of common stock.
• Concurrently, 4,949 shares of common stock were disposed of at a price of $115.25 per share to cover tax liabilities associated with the RSU vesting and exercise.
• Following these transactions, O'Day directly beneficially owns 601,203 shares of common stock and 98,496 Restricted Stock Units.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-planned contract.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects the vesting of executive compensation and a net increase in direct share ownership, indicating continued alignment with shareholder interests. The sale of shares is for tax purposes, a routine event.

Positives

• The exercise of Restricted Stock Units indicates a vesting event, which is a positive for the executive as it converts contingent rights into actual shares.
• The net increase in directly owned common stock (10,427 acquired 4,949 disposed = 5,478 net acquired) suggests continued equity ownership and alignment with shareholder interests.

Negatives

• A portion of the acquired shares (4,949 shares) was sold to cover tax obligations, which is a common practice but represents a reduction in the total shares held from the vesting event.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Daniel P. O'Day, Chairman & CEO, exercised 10,427 Restricted Stock Units (RSUs) granted by Gilead Sciences, Inc., converting them into common stock.
• Concurrently, 4,949 shares of Gilead Sciences, Inc. common stock were disposed of by Mr. O'Day to cover tax liabilities arising from the RSU vesting and exercise. These transactions are part of his compensation and equity plan with the company.

Stakeholder Impact

• Shareholders: The CEO's continued and slightly increased direct ownership of common stock (net 5,478 shares) aligns his interests with shareholders. The sale for tax purposes is a standard practice and not indicative of a lack of confidence.
• Employees: The vesting of RSUs is part of executive compensation, which can be seen as a standard benefit for high-level employees.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales) under a pre-planned 10b5-1(c) plan. Such transactions are generally not indicative of a change in the company's fundamental outlook or the insider's confidence, and thus do not warrant a change in investment recommendation based solely on this filing. The net increase in direct share ownership is a minor positive, reinforcing alignment.

Keywords

Gilead Sciences, GILD, Daniel O'Day, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Vesting, Equity Compensation, CEO, Biotechnology, Pharmaceuticals